MCM2 and small cell lung carcinoma: Chanchan Gao et al. suggested that lower expression of MCM2 was associated with a better response to treatment of anti-programmed cell death 1 (PD-1) and cisplatin in small cell lung cancer (SCLC) (Gao et al. 2021).